Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-11-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6651/7/11/4645 |
| _version_ | 1798025778049318912 |
|---|---|
| author | Izabela Blaszczyk Nazli Poorsafar Foumani Christina Ljungberg Mikael Wiberg |
| author_facet | Izabela Blaszczyk Nazli Poorsafar Foumani Christina Ljungberg Mikael Wiberg |
| author_sort | Izabela Blaszczyk |
| collection | DOAJ |
| description | Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP. |
| first_indexed | 2024-04-11T18:24:19Z |
| format | Article |
| id | doaj.art-8d6961f4834e432da277bab61d367b06 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-04-11T18:24:19Z |
| publishDate | 2015-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-8d6961f4834e432da277bab61d367b062022-12-22T04:09:40ZengMDPI AGToxins2072-66512015-11-017114645465410.3390/toxins7114645toxins7114645Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral PalsyIzabela Blaszczyk0Nazli Poorsafar Foumani1Christina Ljungberg2Mikael Wiberg3Department of Hand and Plastic Surgery, University Hospital of Northern Sweden, 90 185 Umea, SwedenDepartment of Hand and Plastic Surgery, University Hospital of Northern Sweden, 90 185 Umea, SwedenDepartment of Hand and Plastic Surgery, University Hospital of Northern Sweden, 90 185 Umea, SwedenDepartment of Hand and Plastic Surgery, University Hospital of Northern Sweden, 90 185 Umea, SwedenBotulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP.http://www.mdpi.com/2072-6651/7/11/4645botulinum toxin type Acerebral palsysafetyadverse eventsmuscle spasticity |
| spellingShingle | Izabela Blaszczyk Nazli Poorsafar Foumani Christina Ljungberg Mikael Wiberg Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy Toxins botulinum toxin type A cerebral palsy safety adverse events muscle spasticity |
| title | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
| title_full | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
| title_fullStr | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
| title_full_unstemmed | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
| title_short | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
| title_sort | questionnaire about the adverse events and side effects following botulinum toxin a treatment in patients with cerebral palsy |
| topic | botulinum toxin type A cerebral palsy safety adverse events muscle spasticity |
| url | http://www.mdpi.com/2072-6651/7/11/4645 |
| work_keys_str_mv | AT izabelablaszczyk questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT nazlipoorsafarfoumani questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT christinaljungberg questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT mikaelwiberg questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy |